Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings: Revenue $4.6M
ALLO — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
Allogene narrowed its Q2 2026 net loss to $42.7M as R&D fell 23%, and an April share sale lifted cash to $423.6M, funding operations into Q1 2029 past its pivotal ALPHA3 lymphoma readout.
Revenue
$4.6M
Net income
-$43M
+16.2% YoY
Diluted EPS
$-0.13
+43.5% YoY
Allogene Therapeutics, a clinical-stage biotech developing "off-the-shelf" CAR T cell therapies (immune cells from healthy donors, engineered to attack disease, that can be made in advance instead of from each patient's own blood), lost $42.7 million in the second quarter of 2026, down from $50.9 million a year earlier. The bigger story is the balance sheet: after encouraging interim results from its lead lymphoma trial in April, Allogene raised $187.9 million in a share sale, lifting cash and investments to $423.6 million and stretching its stated cash runway — how long the money lasts at the planned spending rate — from the first quarter of 2028 to the first quarter of 2029.
At a glance
$423.6M in cash and investments (up from $258.3M at end-2025): enough, per management, to fund operations into Q1 2029, past the mid-2028 date when the pivotal ALPHA3 trial's main result is due.
R&D spending fell 23% to $30.7M, mostly from fewer staff after the May 2025 layoffs and the timing of manufacturing runs — but management now expects spending to rise as ALPHA3 scales to ~100 trial sites.
Weighted share count up 50% (328.9M vs 218.9M): the smaller per-share loss ($0.13 vs $0.23) is largely a dilution effect, not a smaller loss.
What happened in the quarter
Allogene has no products on the market. Its value rests on three programs:
Cema-cel (ALPHA3 trial, first-line large B-cell lymphoma): the pivotal Phase 2 trial treats patients who look cancer-free after their first chemotherapy but still have minimal residual disease (MRD) — traces of tumor DNA in the blood that signal a high risk of relapse. In the April interim futility analysis (a check on whether the trial is worth continuing), 58.3% (7 of 12) cema-cel patients cleared MRD by Day 45 versus 16.7% (2 of 12) on observation alone. There were no treatment-related serious side effects, no cytokine release syndrome or neurotoxicity, and 10 of 12 patients were treated as outpatients. In July the FDA granted cema-cel RMAT and Fast Track designations, which allow more frequent FDA contact and possibly a faster review.
ALLO-329 (RESOLUTION trial, autoimmune disease): a Phase 1 dose-finding study in lupus, scleroderma and myositis, testing whether the company's Dagger technology can reduce or remove the need for chemotherapy before infusion. Data update promised for Q4 2026.
ALLO-316 (TRAVERSE trial, kidney cancer): a 25% confirmed response rate (5 of 20) in the Phase 1b cohort, 31% in patients with high CD70 expression, published in July. Management is looking for a partner rather than funding a registration trial alone.
Read 0 community reports on Allogene Therapeutics, Inc., or write your own.Write a report
The quarter also brought a CEO change: David Chang stepped down on June 30, and Chief Medical Officer Zachary Roberts became CEO on July 1.
Key figures
Metric
Q2 2026
Q2 2025
YoY Change
Collaboration revenue (one-off, non-cash)
$4.6M
$0
n/a
Research & development expense
$30.7M
$40.2M
-23%
General & administrative expense
$20.8M
$14.3M
+46%
Total operating expenses
$51.6M
$56.8M
-9%
Net loss
$(42.7)M
$(50.9)M
Loss 16.2% smaller
Net loss per share (basic & diluted)
$(0.13)
$(0.23)
Loss 43.5% smaller
Weighted-average shares
328.9M
218.9M
+50%
Cash, cash equivalents & investments (period-end)
$423.6M
$258.3M (Dec 31, 2025)
+64% vs year-end
Operating cash outflow, first half
$44.9M
$92.0M
-51%
For a pre-revenue biotech the meaningful lines are spending (R&D, administrative costs), the loss, and cash — revenue and profit margins don't carry information yet.
Takeaway: The April interim data let Allogene raise money at a moment of strength rather than necessity: with $423.6 million and a runway into Q1 2029, the company is now funded past ALPHA3's mid-2027 interim and mid-2028 primary event-free-survival readouts. Shareholders paid for that security with roughly 100 million new shares at $2.00, and the trial still has to show that clearing tumor DNA translates into fewer relapses.
Where the money went
R&D fell $9.4 million to $30.7 million. The 10-Q breaks this down: personnel costs fell $5.3 million (including $3.1 million less severance, since last year's quarter carried the cost of the 28% workforce cut), development costs fell $2.2 million "due to the timing of development activities and manufacturing runs," and facilities and depreciation fell $1.2 million. External spending on cema-cel itself was flat at $7.0 million versus $6.9 million — the cuts came from overhead and other programs, not the lead trial.
Administrative costs rose $6.6 million to $20.8 million, almost entirely because of the CEO transition: $6.1 million of stock compensation and $1.6 million of severance tied to the leadership change, partly offset by $1.9 million lower stock compensation elsewhere. Of the quarter's $20.8 million in G&A, $10.3 million was non-cash stock compensation.
Interest and other income fell to $4.6 million from $6.2 million because of a smaller foreign-exchange gain, partly offset by more interest earned on the larger cash pile.
What the headline numbers hide
The "revenue" is an accounting release, not a business. The $4.6 million of collaboration revenue came from terminating the license with Overland Therapeutics (its former China joint venture) on May 12, 2026: consideration that had sat on the balance sheet as a liability was recognized as revenue once it became non-refundable. No cash came in, and no deferred revenue remains. Strip it out and the quarter's net loss would have been about $47.3 million.
The narrower loss per share is mostly dilution. The net loss shrank 16%, but the per-share loss shrank 43%, because the average share count rose 50% after the April offering (100.2 million shares at $2.00) and 12.5 million shares sold through the at-the-market (ATM) program in the first half — an ATM lets a company sell shares gradually into the market. Another $135.0 million of ATM capacity was registered in June and was untouched at quarter-end.
First-half cash burn looks lower than it is. Operating cash outflow of $44.9 million for six months includes the $23.7 million return of a €20 million escrow deposit in February (released after an arbitration involving its licensors Servier and Cellectis). Without that one-off refund, the underlying outflow was roughly $68 million.
Non-cash charges are large. Stock-based compensation was $12.4 million in the quarter ($20.7 million year-to-date), so the cash cost of running the company is well below the reported loss.
Guidance went up, not down. In May, management raised its 2026 operating cash expense guidance from ~$150 million to ~$165 million (GAAP operating expenses from ~$210 million to ~$225 million) to reflect the faster ALPHA3 build-out; August reaffirmed those numbers. With roughly $68 million of underlying operating cash outflow in the first half, the second half implies a clear step-up in spending.
Outlook
Management's stated milestones:
~100 ALPHA3 sites active by year-end 2026 (the 80+ site goal was hit about six months early).
ALLO-329 clinical and translational data in Q4 2026.
ALPHA3 interim event-free survival (EFS) analysis in mid-2027, enrollment of the ~220 randomized MRD-positive patients completed by end-2027, and the primary EFS analysis in mid-2028. EFS — the time until the cancer returns or the patient needs new treatment — is what regulators will judge, not MRD clearance.
Cash runway into Q1 2029, excluding any partnership deals.
Our read: the financial risk has eased materially this year — the company went from a runway ending in early 2028 (before its primary readout) to one that covers it. The scientific risk has not. The interim result rests on 24 patients and a surrogate measure; the company itself cites literature suggesting a 25–30 point gap in MRD clearance may predict a meaningful clinical benefit, and the observed gap is 41.6 points, but EFS remains blinded. The near-term test is the Q4 ALLO-329 update, which will show whether Dagger can deliver a chemotherapy-light CAR T for autoimmune disease — a crowded field where Allogene's pitch is ease of use. Watch the second-half spending ramp against the $165 million guide, and whether the company taps the $135 million ATM before the mid-2027 EFS read.